| LCTX Stock | | | USD 0.59 0.02 3.51% |
Lineage Cell financial indicator trend analysis is infinitely more than just investigating Lineage Cell Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lineage Cell Therapeutics is a good investment. Please check the relationship between Lineage Cell Accounts Payable and its Cash And Short Term Investments accounts. Check out
Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lineage Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in estimate.
Accounts Payable vs Cash And Short Term Investments
Accounts Payable vs Cash And Short Term Investments Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of
Lineage Cell Therapeutics Accounts Payable account and
Cash And Short Term Investments. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Lineage Cell's Accounts Payable and Cash And Short Term Investments is -0.11. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of Lineage Cell Therapeutics, assuming nothing else is changed. The correlation between historical values of Lineage Cell's Accounts Payable and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Lineage Cell Therapeutics are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Accounts Payable i.e., Lineage Cell's Accounts Payable and Cash And Short Term Investments go up and down completely randomly.
Correlation Coefficient | -0.11 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Accounts Payable
An accounting item on the balance sheet that represents Lineage Cell obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Lineage Cell Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.
Cash And Short Term Investments
Short Term Investments is an account in the current assets section of Lineage Cell Therapeutics balance sheet. This account contains Lineage Cell investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Lineage Cell Therapeutics fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.
Most indicators from Lineage Cell's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lineage Cell Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out
Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lineage Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in estimate.
At this time, Lineage Cell's
Issuance Of Capital Stock is fairly stable compared to the past year.
Enterprise Value is likely to rise to about 206.5
M in 2024, whereas
Selling General Administrative is likely to drop slightly above 11
M in 2024.
Lineage Cell fundamental ratios Correlations
Click cells to compare fundamentals
Lineage Cell Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Lineage Cell fundamental ratios Accounts
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Lineage Stock Analysis
When running Lineage Cell's price analysis, check to
measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to
predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.